Physician profile
Arthur M Kozin
NPI 1659339513
$86,478.64
in general payments reported to CMS, 2019-2025
49 companies · $7,250 in 2025
The $7,250 reported for 2025 was more than what 94% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $2,829 · 2021: $13K · 2022: $33K · 2023: $12K · 2024: $5,844 · 2025: $7,250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Food and Beverage: $8,425 · Consulting Fee: $2,700 · Travel and Lodging: $1,280 · Education: $234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,685.00 |
| Food and Beverage | $8,424.96 |
| Consulting Fee | $2,700.00 |
| Travel and Lodging | $1,280.18 |
| Education | $233.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $36,932.24 | 2019-2025 | Veltassa, Korsuva |
| Astrazeneca Pharmaceuticals LP | $19,768.57 | 2019-2025 | Farxiga, Lokelma, Flumist Quadrivalent |
| Bayer Healthcare Pharmaceuticals INC. | $10,092.51 | 2021-2025 | |
| Travere Therapeutics, INC. | $6,595.73 | 2019-2025 | |
| Aurinia Pharma U.S., INC. | $3,522.53 | 2021-2025 | Lupkynis |
| Amgen INC. | $1,114.97 | 2019-2025 | Tavneos, Krystexxa, Parsabiv |
| Boehringer Ingelheim Pharmaceuticals, INC. | $829.12 | 2021-2025 | Jardiance, Synjardy |
| Opko Pharmaceuticals, LLC | $600.88 | 2019-2025 | Rayaldee |
| Mallinckrodt Hospital Products INC. | $593.10 | 2020-2025 | Acthar, Terlivaz |
| Otsuka America Pharmaceutical, INC. | $505.20 | 2019-2025 | Jynarque, Voyxact |
| Novo Nordisk INC | $489.92 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $457.46 | 2021-2025 | |
| Fresenius USA Marketing, INC. | $428.29 | 2020-2025 | Velphoro, Velphoro, Korsuva |
| Calliditas Therapeutics US INC. | $426.50 | 2022-2025 | Tarpeyo |
| Glaxosmithkline, LLC. | $385.37 | 2020-2025 | Shingrix, Arexvy, Benlysta |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Kozin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.